Overview

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

Status:
Completed
Trial end date:
2016-09-09
Target enrollment:
Participant gender:
Summary
A pharmacokinetic drug interaction study of erenumab and an oral contraceptive containing progestin and estrogen.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Erenumab
Estradiol
Estrogens
Norgestimate
Progestins